Video

Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.